Arkolith/Insider Trading/KZR/Form 4

Schiller Mark C.

Chief Operating OfficerKezar Life Sciences, Inc. (KZR) · full profile →Form 4 · filed May 11, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
10
1 non-derivative · 9 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 11, 2026Tender(U)3K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 11, 2026Disposed to issuer(D)25K—$00
May 11, 2026Disposed to issuer(D)25K—$00
May 11, 2026Disposed to issuer(D)12K—$00
May 11, 2026Disposed to issuer(D)5K—$00
May 11, 2026Disposed to issuer(D)2K—$00
May 11, 2026Disposed to issuer(D)5K—$00
May 11, 2026Disposed to issuer(D)11K—$00
May 11, 2026Disposed to issuer(D)13K—$00
May 11, 2026Disposed to issuer(D)16K—$00

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002007659-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML